Contains Proteins Or Derivative Or Polysaccharides Or Derivative Patents (Class 424/499)
-
Publication number: 20110020457Abstract: A polymer-surfactant nanoparticle formulation, using the anionic surfactant aerosol OT (AOT) and polysaccharide polymer alginate, is used for sustained release of water-soluble drugs. The AOT-alginate nanoparticles are suitable for encapsulating doxorubicin, verapamil and clonidine, as well as therapeutic agents effective against dermal conditions such as psoriasis. The nanoparticles are also suitable for encapsulating photo-activated compounds such as methylene blue for use in photo-dynamic therapy of cancer and other diseases, and for treating tumor cells that exhibit resistance to at least one chemotherapeutic drug.Type: ApplicationFiled: August 14, 2007Publication date: January 27, 2011Inventors: Jayanth Panyam, Mahesh D. Chavanpatil
-
Publication number: 20110020225Abstract: The present invention relates to porous polymer particles containing a charged molecule immobilized therein and a method for preparing the same. According to the disclosed invention, porous particles can be prepared using a biocompatible polymer and, at the same time, a charged molecule can be immobilized in the pores of the porous particles, such that various charged molecules can be loaded in the porous particles. In addition, various kinds of drugs or functional materials can be loaded into the porous particles of the present invention by electrostatic attraction and absorption or adsorption by a capillary phenomenon occurring due to porous properties.Type: ApplicationFiled: August 5, 2008Publication date: January 27, 2011Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Bong Hyun Chung, Yong Taik Lim, Jung Hyun Han
-
Publication number: 20110020227Abstract: The invention relates to new amphiphilic linear block copolymers of polysaccharides and polymers. The amphiphilic linear block copolymers do not form a true solution in water and are able to form micelles in selective solvents. Also disclosed are particles, each of which has a shell and a core, and a diameter of about 1 to 1,000 nanometers, and methods of delivering agents or removing substances, e.g., undesirable substances, from a subject or environment, by using these particles.Type: ApplicationFiled: June 22, 2010Publication date: January 27, 2011Applicant: University of MassachusettsInventors: Stephen P. McCarthy, Balint Koroskenyi, Robert J. Nicolosi
-
Publication number: 20110020458Abstract: A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 ?m.Type: ApplicationFiled: September 29, 2010Publication date: January 27, 2011Applicant: LG Life Sciences, Ltd., Inc.Inventors: Myung-Jin KIM, Sun-Jin Kim, Oh-Ryong Kwon
-
Publication number: 20110014124Abstract: This invention relates generally to methods for ameliorating at least one symptom or aspect of atherosclerosis. The methods include administration of targeted carrier compositions comprising a therapeutic agent effective in ameliorating at least one aspect of atherosclerosis coupled to a targeting ligand effective is targeting the therapeutic agent to tissue associated with atherosclerotic plaque.Type: ApplicationFiled: September 24, 2010Publication date: January 20, 2011Inventors: Gregory M. LANZA, Samuel A. WICKLINE
-
Publication number: 20110008454Abstract: A pharmaceutical or veterinary granule composition in the form of a mixture consisting essentially of: (i) at least one drug classifiable as Class II or Class IV of the Biopharmaceutical Classification System, wherein said drug (i) constitutes from 0.Type: ApplicationFiled: June 15, 2010Publication date: January 13, 2011Applicant: Universiteit GentInventors: Jean Paul Remon, Chris Vervaet
-
Publication number: 20110008452Abstract: The inventive medicinal agent comprises antibodies against beta-subunit of insulin receptor in an activated form produced by means of repeated serial dilution and an external action performed according to homeopathic technology. The inventive method for producing a solid medicinal formulation for perorally treating fatness, diabetes, and other diseases associated with impaired glucose tolerance, consists in mixing the effective amount of carrier, which is showered in a fluidised layer by a water-alcohol dilution of antibodies in the form active against the beta-subunit of the insulin receptor produced by combining the repeated serial dilution, thereby reducing the concentration of antibodies, and an external action according to homeopathic technology, and is dried at a temperature equal to or less than 35° C., with pharmaceutically acceptable additives and in subsequently pelleting the mixture thus obtained by means of direct dry compression.Type: ApplicationFiled: May 31, 2007Publication date: January 13, 2011Inventors: Oleg Iliich Epshtein, Svetiana Alexandrovna Sergeeve
-
Publication number: 20110008453Abstract: Disclosed are stable corticosteroid nanoparticulate formulations, methods of making and therapeutic uses thereof.Type: ApplicationFiled: May 11, 2010Publication date: January 13, 2011Applicant: Marinus PharmaceuticalsInventors: Kenneth Shaw, Mingbao Zhang
-
Publication number: 20110008455Abstract: This invention relates to crosslinked protein nanoparticles and a method for producing the same. The method comprises the preparation and nanonization (i.e., size reduction to the nanoscale) of protein nanoparticle precursor materials—i.e., crosslinked proteins of the micron or greater size—via mechanical or hydrodynamic shear, mechanical crushing, sonic cavitation and/or hydrodynamic cavitation.Type: ApplicationFiled: July 6, 2010Publication date: January 13, 2011Applicant: SABANCI UNIVERSITYInventor: Alpay Taralp
-
Publication number: 20110003007Abstract: A microparticle includes an agglomerate of a hydrophilic active substance containing particle, which particle includes an amphiphilic polymer composed of a hydrophobic segment of poly (hydroxy acid) and a hydrophilic segment of polysaccharides or polyethylene glycol, and a hydrophilic active substance. It is characterized by an efficient inclusion of the hydrophilic active substance, and a release of the hydrophilic active substance at an appropriate speed in the human body, and is hence very useful as a DDS pharmaceutical preparation.Type: ApplicationFiled: February 20, 2009Publication date: January 6, 2011Applicant: TORAY INDUSTRIES, INC.Inventors: Yoshinori Kakizawa, Reiji Nishio, Junji Michizoe, Masakazu Koiwa, Nobuo Ida, Taisuke Hirano, Yoichiro Koshi
-
Publication number: 20100331252Abstract: The methods and compositions of this invention provide a means of regenerating injured musculoskeletal tissue by inhibition of myostatin function. The invention provides methods of treating a nonunion fracture in an individual comprising delivering to the fracture via a delivery system comprising biodegradable hydrogel, a pharmacological amount of myostatin propeptide effective to inhibit myostatin function. The invention also teaches compositions useful for the treatment of non-union fracture in an individual, said compositions comprising a pharmacological amount of myostatin propeptide effective to inhibit myostatin function; and a delivery system for delivering said myostatin propeptide to said fracture, wherein the delivery system comprises a biodegradable hydrogel or biodegradable nanobeads.Type: ApplicationFiled: June 25, 2010Publication date: December 30, 2010Inventor: Mark W. Hamrick
-
Publication number: 20100330190Abstract: Embodiments of the disclosure encompass compositions and methods for generating immune responses in an animal or human host. Embodiments of the compositions encompass proteins derived from the surface proteins of bacteria and protozoa, and in particular the flagellum component flagellin, and which have adjunctival properties when administered in conjunction with an immunogen. Embodiments of the compositions of the disclosure are modified to incorporate a heterologous transmembrane-cytoplasmic domain allowing the peptides to be incorporated into virus-like particles. Embodiments of the methods of generating an immunological response in an animal or human comprise exposing the immune system of an animal or human host to an immunogen and a virus-like particle comprising an adjuvant polypeptide including a host cell Toll-like receptor ligand polypeptide having a transmembrane-cytoplasmic tail polypeptide, and a heterologous signal peptide.Type: ApplicationFiled: December 17, 2008Publication date: December 30, 2010Inventors: Richard W. Compans, Baozhong Wang, Jadranka Bozia, Ioanna Skountzou
-
Publication number: 20100330137Abstract: The present invention relates to a pharmaceutical or dietary composition containing Mangosteen (Garcinia Mangostana pericarp) and being characterized by high bioavailability. A process for the manufacture of this composition is a further object of the present invention. In particular, the present invention relates to a composition containing Mangosteen extract and oligosaccharides in an amount ranging from 5 to 50 w/w % with respect to the Mangosteen extract or a fermented Mangosteen product and to a process for obtaining thereof.Type: ApplicationFiled: March 10, 2008Publication date: December 30, 2010Inventor: Mauro Mantovani
-
Publication number: 20100330188Abstract: A powder for use in a dry powder inhaler includes active particles and carrier particles for carrying the active particles. The powder further includes additive material on the surfaces of the carrier particles to promote the release of the active particles from the carrier particles on actuation of the inhaler. The powder is such that the active particles are not liable to be released from the carrier particles before actuation of the inhaler. The inclusion of additive material in the powder has been found to give an increased respirable fraction of the active material.Type: ApplicationFiled: March 26, 2010Publication date: December 30, 2010Applicant: Vectura LimitedInventor: John Nicholas Staniforth
-
Publication number: 20100326437Abstract: An inhalable medicament is provided, in particular a new solid-state form of tiotropium bromide. The medicament can be in the form of solid amorphous particles containing an intimate admixture of tiotropium bromide together with a pharmaceutically acceptable co-solid having a glass transition temperature of at least ?50° C., such as a sugar and/or sugar alcohol.Type: ApplicationFiled: July 3, 2008Publication date: December 30, 2010Applicant: Norton Healthcare Ltd.Inventor: Xian-Ming Zeng
-
Publication number: 20100330191Abstract: The present invention relates to pharmaceutical compositions, food supplement compositions and cosmetic compositions comprising diaminooxidase, and to the use thereof.Type: ApplicationFiled: August 24, 2010Publication date: December 30, 2010Inventors: Albert Missbichler, Franz Gabor, Herwig Reichl
-
Patent number: 7846480Abstract: Method for manufacturing carrier granules. The method forms a mixture comprising fibers, mineral filler, and binder. The mixture contains 32-48 weight-% wood fibers having a bulk density of less than 20 pounds per cubic foot, at least 35 weight-% of which fibers are retained on a 50-Mesh U.S. Sieve Series screen. The fibers have a moisture content of less than 15 weight-%. The mixture also contains 52-65 weight-% mineral filler having a moisture content of less than 12 weight-%. In addition, the mixture contains 3-7 weight-% binder. The mixture is agglomerated by conditioning and agglomerating it in a pin mixer to form small particles followed by agglomerating it in a disc or pan pelletizer to form substantially spherical granules. The method then dries the granules to a moisture content of less than about 5 weight-%, and screens the granules to select granules that pass through a 10-Mesh U.S. Sieve Series screen but are retained on a 40-Mesh U.S. Sieve Series screen.Type: GrantFiled: January 20, 2006Date of Patent: December 7, 2010Assignee: Cycle Group, Inc.Inventors: Yechiel Gilo, Steven G. Myers
-
Publication number: 20100303921Abstract: The present invention relates to pharmaceutical compositions comprising a ? (1-3) ? (1-4) glucan and a pharmaceutically active agent or a botanical extract. A method to extract and purify cereal ?-glucan is also described. The high purity of the cereal ?-glucan obtained according to the present invention allows for the preparation of clear, colourless viscous liquid preparations. These liquid preparations are stable to gelling effects when kept at ambient temperatures and low ash concentrations, and can be used to prepare the pharmaceutical compositions of the present invention.Type: ApplicationFiled: June 29, 2010Publication date: December 2, 2010Applicant: CEAPRO, INC.Inventors: Mark J. Redmond, David A. Fielder
-
Patent number: 7842310Abstract: A method of preparing a pharmaceutical composition is described, comprising 1) atomizing a liquid formulation of a therapeutic agent to produce an atomized formulation; 2) freezing said atomized formulation to form solid particles; and 3) drying said solid particles at about atmospheric pressure to produce a powder, wherein said drying is performed in the presence of vibration, internals, mechanical stirring, or a combination thereof. Another method is described, comprising 1) atomizing a liquid formulation of a therapeutic agent to produce an atomized formulation; 2) freezing said atomized formulation to form solid particles; and 3) drying said solid particles to produce a powder; wherein the atomized formulation comprises droplets having an average mean diameter of between about 35? and about 300?, and/or the powder comprises dried particles having an average mean diameter of between about 35? and about 300?. Compositions made by the above methods, and methods of using the compositions, are also described.Type: GrantFiled: November 19, 2002Date of Patent: November 30, 2010Assignee: Becton, Dickinson and CompanyInventors: Robin Hwang, Vincent Sullivan, Juan Huang, Zhaolin Wang, John A. Mikszta, David Montgomery, Brandi Ford, Anjana Bhuta-Wills
-
Publication number: 20100297231Abstract: This invention provides methods, systems and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes. Bioactive materials can be preserved with high initial viability in a freeze-foam process employing low temperature secondary drying.Type: ApplicationFiled: May 6, 2008Publication date: November 25, 2010Applicant: MEDIMMUNE, LLCInventors: Reinhard Vehring, Yi Ao
-
Publication number: 20100297249Abstract: The invention provides a formulation for the administration of at least one therapeutic mammalian protein to a mammal, and for enhancing the absorption, distribution and release of the at least one therapeutic mammalian protein in or on the mammal, the formulation consisting of at least one therapeutic mammalian protein in a micro-emulsion which micro-emulsion is constituted by a dispersion of vesicles or microsponges of a fatty acid based component in an aqueous or other pharmacologically acceptable earner in which nitrous oxide is dissolved, the fatty acid based component comprising at least one long chain fatty acid based substance selected from the group consisting of free fatty acids and derivatives of free fatty acids It further provides a method of the effective delivery of at least one therapeutic mammalian protein to a mammal and for enhancing the therapeutic efficacy of such at least one therapeutic mammalian protein, the method comprising the step of administering the at least one therapeutic mammaType: ApplicationFiled: July 5, 2007Publication date: November 25, 2010Applicant: NORTH-WEST UNIVERSITYInventors: Jeanetta Du Plessis, Anne Frederica Grobler, Abraham Frederik Kotze
-
Publication number: 20100291207Abstract: The present invention relates to novel formulations comprising ezetimibe as active ingredient. In particular the invention relates to a pharmaceutical composition comprising 5 to 20 wt-% ezetimibe, 50 to 85 wt-% diluent, 3 to 25 wt-% disintegrant, 1 to 10 wt-% binder, and 0.5 to 1 wt-% lubricant, characterized in that the ezetimibe has a particle size distribution of d(0.9) of 5 ?m to 35 ?m and d(0.5) of 3 ?m to 20 ?m, as well as methods for preparing said formulations.Type: ApplicationFiled: December 9, 2008Publication date: November 18, 2010Applicant: ratiopharm GmbHInventors: Ganesh Gat, Pasupuleti Giridhara Rao, Javed Hussain
-
Publication number: 20100291173Abstract: A method of improving renal function in a mammal suffering from, or at risk of developing, at least partial renal failure or renal dysfunction, includes administering to renal tissue of the mammal, a combination comprising a non-viral vector comprising a non-viral particulate carrier which carries a therapeutically effective amount of genetic material capable of expressing a renal function-enhancing Osteogenic Protein-1/Bone Morphogenic Protein-7 (OP-1/BMP-7) polypeptide in the renal tissue.Type: ApplicationFiled: September 4, 2007Publication date: November 18, 2010Applicant: ED. GEISTLICH SOEHNE AG FUER CHEMISCHE INDUSTRIEInventors: Myron Spector, Peter Geistlich
-
Publication number: 20100285143Abstract: The invention relates to improvised pharmaceutical compositions permitting ingestion via oral delivery of proteins/peptides or their conjugates, and/or cation-insulin conjugate complexes demonstrating desirable pharmacokinetic profiles and potency in efficacy models of diabetes in dogs and humans. A preferred formulation comprises 0.01%-20% w/w of insulin, insulin compound conjugates and/or cation insulin conjugates, 10%-60% w/w of one or more fatty acid components selected from saturated or unsaturated C4-C12 fatty acids and/or salts of such fatty acids and additionally contains optimal amounts of other pharmaceutically suitable polymer excipients which permit improved solubility, dissolution rate and effective bioavailability of poorly water soluble compositions and consistent in-vivo release profiles upon scalability during manufacture. A further aspect of the invention features the process of preparing the aforesaid formulations.Type: ApplicationFiled: October 16, 2008Publication date: November 11, 2010Applicant: BIOCON LIMITEDInventors: Anand Khedkar, Sharath, Kumar, Mallapura Rangappa, Ramesh Subramani, Nitesh Dave, Devesh Radhakrishnan, Sundaresh Shankar, Sudheer Chivukula, Ranjith Ramakrishna, Shanmugam, Thandava Murthy, Harish Venkatraman Pai, Nilanjan Sengupta, Ramakrishnan Melarkode, Harish Iyer
-
Publication number: 20100285103Abstract: The present invention discloses an anti-tumor conjugate and pharmaceutical composition or kits comprising the conjugate, as well as a method of producing the anti-tumor conjugate. The anti-tumor conjugate of the present invention is metabolically stable in vivo, and is ultimately available for the treatment of tumors and production of anti-tumor medicaments.Type: ApplicationFiled: January 19, 2007Publication date: November 11, 2010Inventors: Yongzhang Luo, Qing Han, Qingxin Lei, Guodong Chang, Yan Fu
-
Patent number: 7829123Abstract: A process for preparing particles of a substance, such as a protein or polypeptide, comprising: (a) preparing a first liquid comprising water, the substance and a modulator, wherein the modulator has a solubility in water which decreases with increasing temperature; and (b) contacting the first liquid with a second liquid comprising a fluid gas and an organic solvent using an anti-solvent fluid gas technique under conditions of temperature and pressure which result in the precipitation of particles comprising the substance, wherein the temperature of the first liquid is at or above the cloud point temperature of the first liquid when the first liquid contacts the second liquid. Also claimed are particles obtained according to the process and compositions containing the particles.Type: GrantFiled: September 15, 2006Date of Patent: November 9, 2010Assignee: AstraZeneca ABInventors: Goran Eric Sundholm, Mustafa Demirbuker, Saeed Moshashaee
-
Publication number: 20100278930Abstract: The invention provides an orally disintegrating tablet containing (a) one or more saccharides or sugar alcohols selected from the group consisting of mannitol, lactose, xylitol, sucrose, erythritol and glucose and (b) low substituted hydroxypropylcellulose and substantially free of a starch disintegrant, which tablet is produced by steps of granulating a composition containing the above-mentioned components (a) and (b) by an agitation granulation method, and compression-molding the obtained granulation product. The invention also provides a method of producing an orally disintegrating tablet substantially free of a starch disintegrant, including steps of granulating a composition containing the above-mentioned components by an agitation granulation method, and compression-molding the obtained granulation product.Type: ApplicationFiled: December 26, 2008Publication date: November 4, 2010Applicant: SAWAI PHARMACEUTICAL CO., LTD.Inventors: Tomonori Okumura, Nobuko Hamaguchi, Yasufumi Okamura
-
Publication number: 20100278883Abstract: The invention relates to the use of amphiphilic self-assembling proteins for formulating poorly water-soluble effect substances.Type: ApplicationFiled: January 19, 2007Publication date: November 4, 2010Applicant: BASF SEInventors: Burghard Liebmann, Marcus Fehr, Daniel Hümmerich, Ingrid Martin, Mario Brands, Arne Ptock, Thomas Scheibel
-
Publication number: 20100275939Abstract: An antibacterial artificial hair of the present invention includes an artificial hair and organic resin particles adhering to the artificial hair. The organic resin particles are powdered fine particles including an organic resin and an aluminum salt that is chemically bonded to the organic resin. An antibacterial coating agent for artificial hair of the present invention is used for an artificial hair and obtained by dispersing the organic resin particles in an aqueous medium. The presence of the organic resin particles including the aluminum salt not only provides the luster and texture similar to those of human hair, but also imparts the antibacterial properties.Type: ApplicationFiled: November 28, 2008Publication date: November 4, 2010Applicant: KANEKA CORPORATIONInventor: Hiroyuki Shinbayashi
-
Publication number: 20100278929Abstract: The present invention provides methods of optimizing the production and purification of antibody formulations that immunospecifically bind to antigens of interest and are suitable for parenteral administration to a subject, which formulations exhibit increased stability due to reduced degradation and aggregation of the antibody component on long term storage. Such methods provide formulations that offer multiple advantages over formulations produced by non-optimized methods including less stringent or more readily available transportation/storage conditions, and less frequent dosing or smaller dosage amounts in the therapeutic, prophylactic and diagnostic use of such formulations. The invention further provides methods of utilizing the formulations of the present invention.Type: ApplicationFiled: January 19, 2010Publication date: November 4, 2010Applicant: Medlmmune, LLCInventors: Ziping Wei, Guillermo Tous, Mark Schenerman, Christian B. Allan
-
Patent number: 7824711Abstract: The present invention is directed to compositions having at least one neocartilage particle, juvenile cartilage particle or a combination thereof and a matrix, and methods and devices that include the compositions.Type: GrantFiled: December 13, 2004Date of Patent: November 2, 2010Assignees: Isto Technologies, Inc., Zimmer, Inc.Inventors: Neil Kizer, Robert Spiro, Jian Q. Yao, Cheryl Renee Blanchard
-
Publication number: 20100272639Abstract: Polysaccharide nanoparticles that are particularly useful in for example drug and agent delivery, tissue-specific targeting, for medical imaging and diagnosis, as well as modifiers of physico-chemical properties. The nanoparticles can be highly-branched glucose homopolymers and can be characterized by a uniform spherical shape. They are monodisperse, hydrophilic and produce low solution viscosities. The nanoparticles are non-toxic, biocompatible and biodegradable. Also, the process of isolation of said polysaccharide nanoparticles from various organisms including, but not limited to, microorganisms such as bacteria and yeasts. Also provided are methods for chemical conjugation of the polysaccharide nanoparticles with various agents. Also provided are examples of use of the polysaccharide nanoparticles and their derivatives as drug delivery systems and fluorescent di-agnostics.Type: ApplicationFiled: December 19, 2008Publication date: October 28, 2010Inventor: John Robert Dutcher
-
Publication number: 20100274362Abstract: Mixtures, such as gels or pastes, comprising freeze-milled cartilage particles and exogenous growth factors are used for repairing chondral defects. Such mixtures may be applied to constructs comprising cancellous bone for implantation at the defect site. Suitable growth factors include variants of FGF-2, particularly variants that include a sole amino acid substitution for asparagine at amino acid 111 of the ?8-?9 loop of the FGF-2 peptide. Such FGF-2 variants are released slowly and continuously at a constant rate from cartilage pastes. In other embodiments, the amino acid substituted for asparigine is glycine. Other variants that may be used include FGF-9 variants having truncated chains and a sole amino acid substitution in the ?8-?9 loop of the FGF-9 peptide either for tryptophan at amino acid 144 or for asparagine at amino acid 143.Type: ApplicationFiled: January 14, 2010Publication date: October 28, 2010Inventors: Avner Yayon, Katherine G. Truncale, Hilla Barkay-Olami, Alex B. Callahan, Arthur A. Gertzman, Yen-Chen Huang, Morris L. Jacobs, John C. Munson, Eric J. Semler, Roman Shikhanovich, Baruch Stern, Moon Hae Sunwoo, William W. Tomford, Judith I. Yannariello-Brown
-
Publication number: 20100266692Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water soluble drug, a poorly aqueous soluble non-ionizable polymer, and an anionic cellulosic polymer.Type: ApplicationFiled: June 30, 2008Publication date: October 21, 2010Inventors: Corey Jay Bloom, Marshall David Crew, Warren Kenyon Miller, Daniel Tod Smithey
-
Publication number: 20100260860Abstract: The present invention is directed to methods of treating vasomotor symptoms in castrated prostatic cancer patients in need of treatment, comprising administering about 15 mg or less of cyproterone acetate per day to the patients. The present invention is further directed to dosage forms comprising about 1 mg to about 15 mg of cyproterone acetate and a package comprising a plurality of dosage forms comprising about 1 mg to about 15 mg of cyproterone acetate.Type: ApplicationFiled: October 12, 2009Publication date: October 14, 2010Inventors: Salah U. AHMED, Sundeep Sethia, Kathleen Reape, Howard Hait, Carole S. Ben-Maimon
-
Patent number: 7811606Abstract: Nasal pharmaceutical formulations comprising a drug substance having a specific particle size distribution profile are disclosed herein. Such profile provides increased bioavailability, increased efficacy or prolonged therapeutic effect of the drug substance when administered intranasally. The formulations of the present invention may comprise one or more corticosteroids having a specific particle size distribution profile. In a preferred embodiment, the corticosteroid is beclomethasone or a pharmaceutically acceptable derivative thereof for the treatment of one or more symptoms of rhinitis. Preferably, the drug substance is beclomethasone dipropionate. The formulations herein may be provided as an aqueous suspension suitable for inhalation via the intranasal route.Type: GrantFiled: April 16, 2003Date of Patent: October 12, 2010Assignee: Dey, L.P.Inventor: Imtiaz Chaudry
-
Publication number: 20100255111Abstract: A method of expressing at least one protein in an animal by intraperitoneal administration of mesenchymal stem cells (or genetically engineered mesenchymal stem cells) with at least one polynucleotide encoding at least one protein. The method may be employed, for example, in treating lysosomal storage disorders, such as Fabry Disease, or arthritic disorders, or hemophilia, or diabetes.Type: ApplicationFiled: June 3, 2009Publication date: October 7, 2010Applicant: OSIRIS THERAPEUTICS, INC.Inventors: PADMAVATHY VANGURI, JOSEPH D. MOSCA
-
Patent number: 7807198Abstract: The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent.Type: GrantFiled: December 28, 2005Date of Patent: October 5, 2010Assignees: California Institute of Technology, Calando Pharmaceuticals, Inc.Inventors: Suzie Hwang Pun, Hector Gonzalez, Mark E. Davis, Nathalie C. Bellocq, Jianjun Cheng
-
Publication number: 20100247664Abstract: Water-insoluble cellulose derivatives such as ethyl cellulose can be used to treat or prevent metabolic syndrome and/or one of the abnormalities of metabolic syndrome.Type: ApplicationFiled: October 18, 2007Publication date: September 30, 2010Inventors: Stephanie K. Lynch, Wallace Yokoyama, Maciej Turowski, Jerry R. Conklin
-
Publication number: 20100247665Abstract: A spherical particle of the present invention contains a sugar alcohol and a crystalline cellulose and/or powdered cellulose, wherein the mass ratio between the sugar alcohol and the crystalline cellulose and/or powdered cellulose is within a range from 50:50 to 90:10, the particle size is within a range from 75 to 250 ?m, the sphericity is not less than 0.8, and the bulk density is not less than 0.6 g/ml. Further, a method for producing the spherical particle of the present invention includes a granulation step of rolling a sugar alcohol having an average particle size of not more than 40 ?m and a crystalline cellulose and/or powdered cellulose having an average particle size of not more than 50 ?m while spraying a liquid thereon.Type: ApplicationFiled: November 18, 2008Publication date: September 30, 2010Applicant: FREUND CORPORATIONInventor: Terumi Takahashi
-
Patent number: 7803404Abstract: Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.Type: GrantFiled: September 14, 2006Date of Patent: September 28, 2010Assignee: MannKind CorporationInventors: Mark Hokenson, Keith A. Oberg
-
Patent number: 7803406Abstract: Methods of forming coatings comprising a polycationic peptide for medical devices are disclosed. Also disclosed is a coating comprising a polycationic peptide.Type: GrantFiled: August 26, 2005Date of Patent: September 28, 2010Assignee: Advanced Cardiovascular Systems, Inc.Inventors: Stephen D. Pacetti, Eugene T. Michal, Syed F. A. Hossainy, Ni Ding, Wouter E. Roorda
-
Publication number: 20100239683Abstract: The invention relates to a fluid, milky microcrystalline aqueous suspension of a peptide or peptidomimetic and a counter-ion of a strong proton donor in water, wherein the peptide or peptidomimetic and counter-ion are present in amounts and at a molar ratio sufficient to form the suspension upon mixing and without formation of a gel. The invention also relates to lyophilized compositions that include a dried suspension, methods of making the lyophilized composition, methods of preparing the suspension, and sustained release formulations prepared by the methods.Type: ApplicationFiled: June 7, 2010Publication date: September 23, 2010Inventors: Romano Deghenghi, Francois Boutignon
-
Patent number: 7799344Abstract: Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Type of surface properties that are altered by the disclosed methods include by electrostatic properties, hydrophobic properties and hydrogen bonding properties.Type: GrantFiled: September 14, 2006Date of Patent: September 21, 2010Assignee: MannKind CorporationInventor: Keith A. Oberg
-
Publication number: 20100233279Abstract: Disclosed are novel analogues of the natural product radicicol A of formulae I, .Ia, pi, Ha, lib and HI, pharmaceutical compositions comprising the compounds. The compounds of the invention are kinase and phosphatase inhibitors and find utility in the treatment or prevention of kinase and phosphatase-mediated disorders. Also provided are uses and methods for the treatment or prevention of kinase- and phosphatase-mediated disorders and synthetic processes for the preparation of the compounds.Type: ApplicationFiled: June 5, 2008Publication date: September 16, 2010Inventors: Nicolas Winssinger, Sofia Barluenga
-
Publication number: 20100233276Abstract: The described agglomeration of drug microparticles blended with excipient microparticles is a technique for the size enlargement of micronized products that could be damaged by granulation or compaction techniques. These agglomerates can be used as oral prompt or delayed-release dosage forms administered as they are or dispersed in a liquid. The composition and quantity of the excipient microparticles resulted to be the crucial factors for the agglomerate quality. Therefore, adjusting the content of surface-active agent between 8-20%, of the excipient microparticles it is possible to agglomerate microparticles of drugs that could not be agglomerated per se. Increasing the surfactant concentration in the spray-dried excipient microparticles or increasing the fraction of these excipient microparticles in the blend, the agglomeration was improved. The spray drying technique concentrates the surface-active agent on the microparticle surface.Type: ApplicationFiled: October 26, 2007Publication date: September 16, 2010Applicant: UNIVERSITA' DEGLI STUDI DI PARMAInventors: Renata Raffin, Paolo Colombo, Fabio Sonvico, Gaia Colombo, Alessandra Rossi, Francesca Buttini
-
Patent number: 7795237Abstract: The present invention relates to a pharmaceutical composition comprising a solid suspension prepared by hot melt extrusion of isobutyric acid (2R,3S,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-2-azido-3,4-bis-iso-butyryloxy-tetrahydro-furan-2-ylmethyl ester; hydrochloride salt (I) and a polyethylene glycol (PEG)/polypropylene glycol (PPG) block copolymer.Type: GrantFiled: December 13, 2006Date of Patent: September 14, 2010Inventors: Hashim A. Ahmed, Thomas Vernon Alfredson, Kondamraj Birudaraj, Michael Thomas Brandl, Wantanee Phuapradit, Navnit Hargovindas Shah, Dimitrios Stefanidis
-
Patent number: 7795204Abstract: Food supplement compositions and their methods of use in increasing lean mass and/or muscle size and/or strength in individuals, particularly, athletes is described. The food supplements described comprise a substance which increases nitric oxide production in the body, and, a source of amino acids. Other food supplements described comprise a substance which can enhance and/or mimic insulin activity, and a source of amino acids. The food supplement compositions described are suitable for supplementing the diet of an athlete and particularly for enhancing an athlete's muscle size or strength.Type: GrantFiled: March 11, 2004Date of Patent: September 14, 2010Assignee: Northern Innovations and Formulations Corp.Inventors: Paul T. Gardiner, Derek E. Woodgate, Mark S. Gilbert, Robert W. Thoburn
-
Patent number: 7794743Abstract: Polycationic peptide coatings for implantable medical devices and methods of making the same are described. The methods include applying an emulsion on the device, the emulsion including a polymer and a polycationic peptide. Other methods include incorporation of the polycationic peptide in microspheres and liposomes.Type: GrantFiled: September 2, 2005Date of Patent: September 14, 2010Assignee: Advanced Cardiovascular Systems, Inc.Inventors: Murthy V. Simhambhatla, Ni Ding, Stephen D. Pacetti
-
Publication number: 20100226996Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.Type: ApplicationFiled: October 26, 2006Publication date: September 9, 2010Applicant: Abraxis BioScience, Inc.Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu